A Phase 2, Randomized, Parallel-Group, Double-Blind, Placebo Controlled Study to Evaluate the Safety and Efficacy of CTP-656 With an Open-Label Active Comparator in Patients With Cystic Fibrosis With CFTR Gating Mutations.

Trial Profile

A Phase 2, Randomized, Parallel-Group, Double-Blind, Placebo Controlled Study to Evaluate the Safety and Efficacy of CTP-656 With an Open-Label Active Comparator in Patients With Cystic Fibrosis With CFTR Gating Mutations.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 13 Sep 2017

At a glance

  • Drugs Ivacaftor deuterated (Primary)
  • Indications Cystic fibrosis
  • Focus Therapeutic Use
  • Sponsors Concert Pharmaceuticals; Vertex Pharmaceuticals
  • Most Recent Events

    • 06 Sep 2017 Status changed from active, no longer recruiting to discontinued.
    • 09 Aug 2017 Planned primary completion date changed from 1 Dec 2017 to 1 Aug 2017.
    • 09 Aug 2017 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top